华海药业：子公司获药物临床试验许可

Core Viewpoint - Huahai Pharmaceutical's subsidiary, Shanghai Huao Tai Biopharmaceutical Co., Ltd., has received FDA approval to conduct Phase I clinical trials for the injectable HB0043 in the United States, targeting autoimmune diseases [1] Group 1: Company Developments - The HB0043 is a recombinant humanized IgG1 bispecific antibody that targets both human interleukin-17A and human interleukin-36 receptor, demonstrating high binding and blocking activity [1] - The company has invested approximately 71.11 million yuan in the research and development of this project [1]